Vimarsana
Biggest News Aggregation in the World

Page 18 - Multi Asset News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multi Asset. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multi Asset Today - Breaking & Trending Today

Exclusive: US fund manager Allspring sees rising demand for 'liquid alternatives' after bond, equity slump last year - Vimarsana News

Exclusive: US fund manager Allspring sees rising demand for 'liquid alternatives' after bond, equity slump last year

Allspring has noticed an uptick in demand for liquid alternatives and multi-asset strategies as it eyes a larger client base in Asia.

Source: scmp.com
Debt vs Hybrid vs Multi-asset: A Balasubramanian suggests these mutual funds to make money in FY24 - Vimarsana News

Debt vs Hybrid vs Multi-asset: A Balasubramanian suggests these mutual funds to make money in FY24

A Balasubramanian, MD & CEO, Aditya Birla Sun Life AMC & Chairman, AMFI, explains what kind of mutual fund investments can bring in proper returns in FY24

Are Recent Bank Failures a "U.K. LDI Moment" for the U.S. Financial System? - Vimarsana News

Are Recent Bank Failures a "U.K. LDI Moment" for the U.S. Financial System?

The turmoil within the U.S. banking system, started by the sudden failure of Silicon Valley Bank and Signature Bank, appears far from over.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results - Vimarsana News

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results - Vimarsana News

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

CORAL GABLES, Fla., March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary an...